STOCK TITAN

Harmony Biosciences Holdings, Inc. - HRMY STOCK NEWS

Welcome to our dedicated page for Harmony Biosciences Holdings news (Ticker: HRMY), a resource for investors and traders seeking the latest updates and insights on Harmony Biosciences Holdings stock.

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) is a commercial-stage pharmaceutical company committed to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Established in 2017 and headquartered in Plymouth Meeting, PA, Harmony focuses on rare and orphan diseases, particularly those involving the central nervous system.

Harmony's flagship product is WAKIX® (pitolisant). This molecule is specifically designed to increase histamine signaling in the brain by binding to H3 receptors. It is used for the treatment of excessive daytime sleepiness (EDS) and cataplexy in adult patients with narcolepsy. WAKIX has been commercially available in the U.S. since Q4 2019 and continues to demonstrate strong market performance.

In recent developments, Harmony has initiated a global Phase 3 TEMPO study to evaluate pitolisant for treating EDS and behavioral symptoms in patients with Prader-Willi syndrome (PWS). The U.S. FDA granted Orphan Drug designation to pitolisant for this condition, further underscoring the potential of this therapy to address significant unmet medical needs.

The company's financial performance remains robust, with a 31% increase in net product revenue in Q4 2023 compared to the same period in 2022. Harmony’s strategic growth continues with key acquisitions, such as Epygenix Therapeutics, Inc., which expands its pipeline with promising treatments for rare forms of epilepsy like Dravet syndrome and Lennox-Gastaut syndrome.

Harmony recently announced the FDA's priority review for its supplemental New Drug Application (sNDA) for WAKIX for the treatment of EDS or cataplexy in pediatric patients aged six and older with narcolepsy. This decision highlights the pressing need for pediatric treatment options and demonstrates Harmony's commitment to broadening the clinical utility of its products.

Beyond narcolepsy, Harmony is exploring pitolisant's potential for other rare conditions, including Idiopathic Hypersomnia and Myotonic Dystrophy Type 1 (DM1). The company presented encouraging Phase 2 data showing pitolisant's efficacy in reducing EDS and fatigue in DM1 patients, paving the way for a pivotal Phase 3 study.

Harmony's collaborative efforts extend to partnerships with Bioprojet for the development of TPM-1116, an orexin-2 receptor agonist with potential applications in narcolepsy and other sleep/wake disorders. These initiatives align with the company's mission to deliver innovative treatments that improve the lives of patients living with rare neurological diseases.

For more information, please visit www.harmonybiosciences.com.

Rhea-AI Summary

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) has appointed Linda Szyper to its Board of Directors. With over 30 years of experience in healthcare and pharmaceuticals, Szyper previously served as Chief Operating Officer at McCann Health. On the board, she will be part of the Nominating and Corporate Governance Committees. Szyper expressed enthusiasm about aiding Harmony's mission to develop treatments for rare diseases. Jeff Aronin, Harmony's Chairman, highlighted her operational and commercialization expertise as crucial for the company's growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.6%
Tags
management
-
Rhea-AI Summary

Harmony Biosciences (Nasdaq: HRMY) announced participation in two upcoming virtual investor conferences. CEO John C. Jacobs will engage in fireside chats and host investor meetings at the Jefferies London Healthcare Conference on November 18-19 and the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22 and 30. The fireside chat audio will be available on-demand on Harmony's investor website. Harmony focuses on innovative therapies for rare neurological diseases and aims to address unmet medical needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
conferences
-
Rhea-AI Summary

Harmony Biosciences Holdings reported a net revenue of $80.7 million for Q3 2021, marking a 77% increase compared to Q3 2020, driven by robust sales of WAKIX.

The average number of patients on WAKIX rose to approximately 3,500. Despite a GAAP net loss of $9.6 million due to a one-time charge, non-GAAP adjusted net income reached $30.4 million, or $0.51 per diluted share.

WAKIX's inclusion in the AASM updated clinical guidelines enhances its market position, as the company focuses on expanding clinical utility and acquiring new assets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.94%
Tags
Rhea-AI Summary

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) announced it will release its third quarter 2021 financial results on November 9, 2021. A conference call will follow at 8:30 a.m. ET on the same day. To join, participants can dial (833) 614-1471 (domestic) or +1 (914) 987-7209 (international) using passcode 4387084. A replay will be available after the call and can be accessed until November 16, 2021. Harmony focuses on innovative therapies for rare neurological diseases and is committed to addressing unmet medical needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
-
Rhea-AI Summary

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) announced its addition to the S&P SmallCap 600 Index, effective October 22, 2021. This milestone is seen as a recognition of the company's efforts in providing innovative therapies for rare neurological diseases. The index measures the performance of 600 small-cap U.S. companies, requiring a market cap between $850 million and $3.6 billion. CEO John C. Jacobs expressed confidence that this inclusion will enhance the company's visibility and awareness among stakeholders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.93%
Tags
none
-
Rhea-AI Summary

Harmony Biosciences Holdings, Inc. (HRMY) announced the winners of its Patients at the Heart and Progress at the Heart programs on the third annual World Narcolepsy Day. More than $180,000 was awarded to eight organizations supporting individuals with sleep disorders and rare diseases. The Patients at the Heart program, created in 2019, funds not-for-profits addressing challenges faced by those with excessive daytime sleepiness. The new Progress at the Heart program addresses disparities in the rare disease community.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.98%
Tags
none
Rhea-AI Summary

Harmony Biosciences Holdings (Nasdaq: HRMY) announced an update from the American Academy of Sleep Medicine (AASM) that includes WAKIX® (pitolisant) as a recommended treatment for narcolepsy in adults. The updated clinical guideline published in the Journal of Clinical Sleep Medicine emphasizes WAKIX's efficacy in significantly improving excessive daytime sleepiness and cataplexy. WAKIX has been available in the U.S. since Q4 2019 and received both orphan drug and breakthrough therapy designations. This inclusion is expected to help healthcare professionals make informed treatment decisions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
none
-
Rhea-AI Summary

Harmony Biosciences Holdings (Nasdaq: HRMY), a pharmaceutical company focused on rare neurological diseases, announced that President and CEO John C. Jacobs will engage in fireside chats and investor meetings at several upcoming virtual conferences. Key events include the Citi's 16th Annual BioPharma Virtual Conference on September 8-9, the 2021 Virtual Wells Fargo Healthcare Conference on September 10, and the 2021 Cantor Virtual Global Healthcare Conference on September 28. A live audio webcast of the fireside chat will be accessible on Harmony's investor page.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
conferences
-
Rhea-AI Summary

Harmony Biosciences reported a 94.2% increase in net revenue to $73.8 million for Q2 2021, up from $38 million in Q2 2020. Positive net income reached $14.1 million or $0.24 per diluted share, reversing a loss from the previous year. The company initiated a Phase 2 trial for myotonic dystrophy and acquired HBS-102, a potential first-in-class treatment for narcolepsy. Additionally, a strategic financing collaboration with Blackstone secured up to $330 million to support growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.66%
Tags
Rhea-AI Summary

Harmony Biosciences (Nasdaq: HRMY) and Blackstone (NYSE: BX) announced a strategic financing collaboration worth up to $330 million. The deal includes $300 million in debt capital and a $30 million equity investment. The financing will enable Harmony to expand its portfolio focused on rare neurological diseases and reduce its annual interest expenses. The initial $200 million term loan proceeds will primarily be used to eliminate existing debt, significantly lowering Harmony's capital costs. This partnership aims to enhance the company's growth trajectory in the pharmaceutical sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.66%
Tags
none

FAQ

What is the current stock price of Harmony Biosciences Holdings (HRMY)?

The current stock price of Harmony Biosciences Holdings (HRMY) is $34.06 as of December 24, 2024.

What is the market cap of Harmony Biosciences Holdings (HRMY)?

The market cap of Harmony Biosciences Holdings (HRMY) is approximately 1.9B.

What is Harmony Biosciences' main product?

Harmony Biosciences’ main product is WAKIX® (pitolisant), used for treating excessive daytime sleepiness and cataplexy in adult patients with narcolepsy.

What recent studies has Harmony Biosciences initiated?

Harmony has initiated the global Phase 3 TEMPO study to assess pitolisant for treating excessive daytime sleepiness and behavioral symptoms in Prader-Willi syndrome patients.

What significant acquisitions has Harmony Biosciences made?

Harmony recently acquired Epygenix Therapeutics, adding a rare epilepsy franchise to its expanding pipeline, including treatments for Dravet syndrome and Lennox-Gastaut syndrome.

What recent FDA approvals or reviews has Harmony Biosciences received?

The FDA has granted Orphan Drug designation to pitolisant for Prader-Willi syndrome and priority review for its sNDA for WAKIX for treating EDS or cataplexy in pediatric patients.

What conditions is Harmony Biosciences exploring with pitolisant?

Besides narcolepsy, Harmony is exploring pitolisant for conditions like Idiopathic Hypersomnia and Myotonic Dystrophy Type 1 (DM1).

Where is Harmony Biosciences headquartered?

Harmony Biosciences is headquartered in Plymouth Meeting, PA.

What are some key financial highlights for Harmony Biosciences?

Harmony reported a 31% increase in net product revenue in Q4 2023 compared to the same period in 2022, driven by strong sales of WAKIX.

What partnerships is Harmony Biosciences involved in?

Harmony has a collaborative partnership with Bioprojet, focusing on developing TPM-1116, an orexin-2 receptor agonist for sleep/wake disorders.

How can I get more information about Harmony Biosciences?

For more information, please visit their website at www.harmonybiosciences.com.

What is the mission of Harmony Biosciences?

Harmony Biosciences aims to develop and deliver innovative treatments for rare neurological diseases with a focus on improving patient lives through empathy and innovation.

Harmony Biosciences Holdings, Inc.

Nasdaq:HRMY

HRMY Rankings

HRMY Stock Data

1.94B
38.55M
11.62%
93.1%
10.17%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
PLYMOUTH MEETING